ELSEVIER

Drug and Alcohol Dependence 50 (1998) 257

DRUG and ALCOHOL DEPENDENCE

Author index

Volume 50 (1998)

Allen, T.J. **50**, 137
Ary, D. **50**, 57
Azrin, R.L. **50**, 39

Badger, G.J. **50**, 9, 129
Bateman, D.A. **50**, 203
Bauer, L.O. **50**, 147
Beardsley, P.M. **50**, 123
Bearn, J. **50**, 227
Bickel, W.K. **50**, 129
Biglan, A. **50**, 57
Boardman, C. **50**, 1
Bowman, J.A. **50**, 177
Bray, J.W. **50**, 211
Broers, B. **50**, 233
Brooner, R.K. **50**, 73

Carnwath, T. **50**, 251
Carroll, F.I. **50**, 123
Cheeves, C. **50**, 187
Chen, K. **50**, 109
Cherek, D.R. **50**, 137
Chiriboga, C. **50**, 203
Cook, C.D. **50**, 123
Crowley, T.J. **50**, 27

Day II, J. **50**, 157
Dolan, K. **50**, 197
Dukat, M. **50**, 99
Dumont, P. **50**, 233
Duncan, S.C. **50**, 57
Duncan, T. **50**, 167
Duncan, T.E. **50**, 57

Fernández-Ruiz, J.J. **50**, 241
Friedlander, H. **50**, 203
Fudala, P.J. **50**, 1
Fuentes, J.A. **50**, 241

Gauthier, C.B. **50**, 99
Glass, G.E. **50**, 167
Glennon, R.A. **50**, 99
Gordon, L. **50**, 221
Gossop, M. **50**, 227
Grella, B. **50**, 99

Hall, W. **50**, 197
Hardman, J.-a. **50**, 251
Hasin, D. **50**, 19
Heagarty, M.C. **50**, 203
Herrick-Davis, K. **50**, 99
Higgins, S.T. **50**, 9
Hollander, J.R. **50**, 73
Huddleston, J. **50**, 129

Kandel, D.B. **50**, 109
Kaplan, E. **50**, 197
Kidorf, M. **50**, 73
King, V.L. **50**, 73
Kline, J.K. **50**, 203
Kosten, T. **50**, 221
Kosten, T.R. **50**, 187

Latkin, C. **50**, 167
Lennox, R.D. **50**, 211
Lumey, L.H. **50**, 203

Macdonald, M.J. **50**, 27
Macfadden, W. **50**, 1
Mattick, R.P. **50**, 181
M. Carroll, K. **50**, 221
McKetin, R. **50**, 181
Mehl-Madrona, L. **50**, 9
Melton, L. **50**, 203
Mikulich, S.K. **50**, 27
Mino, A. **50**, 233
Moeller, F.G. **50**, 137

Nich, C. **50**, 221
Nora Chiang, C. **50**, 1

Page, D. **50**, 233
Palumbo, J. **50**, 187
Paykin, A. **50**, 19
Peters, A.D. **50**, 47
Petrakis, I. **50**, 221
Petry, N.M. **50**, 129
Pinelli, A. **50**, 81
Price, L.H. **50**, 187

Ramos, J.A. **50**, 241
Reid, M.M. **50**, 47
Rhoades, H.M. **50**, 137
Romero, J. **50**, 241
Rounsaville, B. **50**, 221
Ruiz-Gayo, M. **50**, 241

Sanson-Fisher, R.W. **50**, 177
Schmitz, J. **50**, 157
Seibyl, J.P. **50**, 187
Selby, M.J. **50**, 39
Shakeshaft, A.P. **50**, 177
Spezia, R. **50**, 81
Spiga, R. **50**, 157
Steele, P.D. **50**, 211
Strang, J. **50**, 227

Teitler, M. **50**, 99
Tidey, J.W. **50**, 9
Trivulzio, S. **50**, 81
Tzanis, E. **50**, 129

Vela, G. **50**, 241

Wasserman, G.A. **50**, 203
Whitmore, E.A. **50**, 27
Wodak, A. **50**, 197
Woods, S.W. **50**, 187

Young, R. **50**, 99
Yu, E. **50**, 1

Zarkin, G.A. **50**, 211

0376-8716/98/$19.00 © 1998 Elsevier Science Ireland Ltd. All rights reserved.
PII S0376-8716(98)00089-1

ELSEVIER

Drug and Alcohol Dependence 50 (1998) 259–261

DRUG and ALCOHOL DEPENDENCE

Subject index

Volume 50 (1998)

Abstinence; Cerebral; Cocaine; Alcohol; Perfusion defects **50**, 187

Abuse liability; Analgesia; Morphine; LY297802; Muscarinic agonist; Subjective drug effects; Humans **50**, 129

Acceptability; Computers; Screening; Clinical; Drug and alcohol **50**, 177

Acquired immunodeficiency syndrome; Injection drug users; Human immunodeficiency virus; Geographic information systems; Attrition; Selection bias; Neighborhood characteristics **50**, 167

Adolescence; Substance use; Development; Latent growth modeling **50**, 57

Adult; Impulsivity; Self-control; Substance dependence; Substance abuse **50**, 137

Alcohol; Cerebral; Cocaine; Perfusion defects; Abstinence **50**, 187

Alcohol dependence; Alcoholism **50**, 19

Alcohol; Dependence; Consequences; Bi-axial; Structural equation modeling **50**, 211

Alcoholism; Alcohol dependence **50**, 19

Ambulatory detoxification; Opiate withdrawal; Lofexidine; Clonidine **50**, 251

Amphetamine; Attention; Memory **50**, 181

Analgesia; Morphine; LY297802; Muscarinic agonist; Subjective drug effects; Abuse liability; Humans **50**, 129

Attention; Amphetamine; Memory **50**, 181

Attrition; Acquired immunodeficiency syndrome; Injection drug users; Human immunodeficiency virus; Geographic information systems; Selection bias; Neighborhood characteristics **50**, 167

Autoradiography; Cannabinoid receptor binding; Cannabinoid agonist-stimulated [35S]GTPγS binding; Cannabinoids; Δ9-Tetrahydrocannabinol; Opiates; Morphine dependence **50**, 241

Bi-axial; Alcohol; Dependence; Consequences; Structural equation modeling **50**, 211

Buprenorphine; Naloxone; Opioid-dependence; Treatment **50**, 1

Cannabinoid agonist-stimulated [35S]GTPγS binding; Cannabinoid receptor binding; Autoradiography; Cannabinoids; Δ9-Tetrahydrocannabinol; Opiates; Morphine dependence **50**, 241

Cannabinoid receptor binding; Cannabinoid agonist-stimulated [35S]GTPγS binding; Autoradiography; Cannabinoids; Δ9-Tetrahydrocannabinol; Opiates; Morphine dependence **50**, 241

Cannabinoids; Cannabinoid receptor binding; Cannabinoid agonist-stimulated [35S]GTPγS binding; Autoradiography; Δ9-Tetrahydrocannabinol; Opiates; Morphine dependence **50**, 241

β-Carbolines; Harmaline; Harmine; Drug discrimination; Hallucinogens; 5-HT_2 receptors; Serotonin **50**, 99

Cerebral; Cocaine; Alcohol; Perfusion defects; Abstinence **50**, 187

Child development; Cocaine; Intelligence; Prenatal exposure **50**, 203

Clinical; Computers; Screening; Acceptability; Drug and alcohol **50**, 177

Clonidine; Opiate withdrawal; Lofexidine; Ambulatory detoxification **50**, 251

Cocaine; Cerebral; Alcohol; Perfusion defects; Abstinence **50**, 187

Cocaine; Dependence; Treatment; Psychopathology; Comorbidity **50**, 9

Cocaine; Drug abusers; Neuropsychological; Polysubstance abuse **50**, 39

Cocaine; Fluoxetine; Methadone; Opioid; Depression **50**, 221

Cocaine; Intelligence; Child development; Prenatal exposure **50**, 203

Cocaine; RTI-15; Drug discrimination; Locomotor activity **50**, 123

Comorbidity; Cocaine; Dependence; Treatment; Psychopathology **50**, 9

Computers; Screening; Acceptability; Clinical; Drug and alcohol **50**, 177

Conduct disorder; Marijuana; Drug dependence; Reinforcement (psychology) **50**, 27

Consequences; Alcohol; Dependence; Bi-axial; Structural equation modeling **50**, 211

0376-8716/98/$19.00 © 1998 Elsevier Science Ireland Ltd. All rights reserved.

PII S0376-8716(98)00090-8

Contingency management; Employment; Methadone treatment **50**, 73

Control of withdrawal effects; Opioid withdrawal syndrome; Rats; Tizanidine **50**, 81

Crime; Methadone treatment outcomes; Scotland; Injecting; HIV risk behaviour **50**, 47

Dependence; Alcohol; Consequences; Bi-axial; Structural equation modeling **50**, 211

Dependence; Cocaine; Treatment; Psychopathology; Comorbidity **50**, 9

Depression; Fluoxetine; Cocaine; Methadone; Opioid **50**, 221

Development; Adolescence; Substance use; Latent growth modeling **50**, 57

Drug abuse; Heroin; HIV-1; Evoked potentials; EEG; Opiates **50**, 147

Drug abusers; Neuropsychological; Polysubstance abuse; Cocaine **50**, 39

Drug and alcohol; Computers; Screening; Acceptability; Clinical **50**, 177

Drug dependence; Marijuana; Reinforcement (psychology); Conduct disorder **50**, 27

Drug discrimination; β-Carbolines; Harmaline; Harmine; Hallucinogens; 5-HT_2 receptors; Serotonin **50**, 99

Drug discrimination; RTI-15; Cocaine; Locomotor activity **50**, 123

Drug dosage; Methadone maintenance; Substance abuse; Opioids; Gender **50**, 233

EEG; Heroin; HIV-1; Evoked potentials; Drug abuse; Opiates **50**, 147

Employment; Methadone treatment; Contingency management **50**, 73

Evoked potentials; Heroin; HIV-1; EEG; Drug abuse; Opiates **50**, 147

Fluoxetine; Cocaine; Methadone; Opioid; Depression **50**, 221

Frequency of marijuana use; Marijuana cessation; Predictors; Reasons for using; Social roles **50**, 109

Gender; Methadone maintenance; Substance abuse; Opioids; Drug dosage **50**, 233

Geographic information systems; Acquired immunodeficiency syndrome; Injection drug users; Human immunodeficiency virus; Attrition; Selection bias; Neighborhood characteristics **50**, 167

Hallucinogens; β-Carbolines; Harmaline; Harmine; Drug discrimination; 5-HT_2 receptors; Serotonin **50**, 99

Harmaline; β-Carbolines; Harmine; Drug discrimination; Hallucinogens; 5-HT_2 receptors; Serotonin **50**, 99

Harmine; β-Carbolines; Harmaline; Drug discrimination; Hallucinogens; 5-HT_2 receptors; Serotonin **50**, 99

Heroin; HIV-1; Evoked potentials; EEG; Drug abuse; Opiates **50**, 147

HIV-1; Heroin; Evoked potentials; EEG; Drug abuse; Opiates **50**, 147

HIV risk behaviour; Methadone treatment outcomes; Scotland; Injecting; Crime **50**, 47

HIV transmission; Prison; Mathematical model; Injecting; Syringe sharing **50**, 197

5-HT_2 receptors; β-Carbolines; Harmaline; Harmine; Drug discrimination; Hallucinogens; Serotonin **50**, 99

Human immunodeficiency virus; Acquired immunodeficiency syndrome; Injection drug users; Geographic information systems; Attrition; Selection bias; Neighborhood characteristics **50**, 167

Humans; Analgesia; Morphine; LY297802; Muscarinic agonist; Subjective drug effects; Abuse liability **50**, 129

Humans; Methadone self-administration; Nicotine; Nicotine abstinence **50**, 157

Impulsivity; Self-control; Substance dependence; Substance abuse; Adult **50**, 137

Injecting; HIV transmission; Prison; Mathematical model; Syringe sharing **50**, 197

Injecting; Methadone treatment outcomes; Scotland; Crime; HIV risk behaviour **50**, 47

Injection drug users; Acquired immunodeficiency syndrome; Human immunodeficiency virus; Geographic information systems; Attrition; Selection bias; Neighborhood characteristics **50**, 167

Intelligence; Cocaine; Child development; Prenatal exposure **50**, 203

Latent growth modeling; Adolescence; Substance use; Development **50**, 57

Locomotor activity; RTI-15; Cocaine; Drug discrimination **50**, 123

Lofexidine; Opiate withdrawal; Clonidine; Ambulatory detoxification **50**, 251

Lofexidine; Polydrug abusers; Opiate withdrawal; Methadone **50**, 227

LY297802; Analgesia; Morphine; Muscarinic agonist; Subjective drug effects; Abuse liability; Humans **50**, 129

Marijuana cessation; Predictors; Reasons for using; Frequency of marijuana use; Social roles **50**, 109

Marijuana; Drug dependence; Reinforcement (psychology); Conduct disorder **50**, 27

Mathematical model; HIV transmission; Prison; Injecting; Syringe sharing **50**, 197

Memory; Amphetamine; Attention **50**, 181

Methadone; Fluoxetine; Cocaine; Opioid; Depression **50**, 221

Methadone maintenance; Substance abuse; Opioids; Drug dosage; Gender **50**, 233

Methadone; Polydrug abusers; Opiate withdrawal; Lofexidine **50**, 227

Methadone self-administration; Nicotine; Nicotine abstinence; Humans **50**, 157

Methadone treatment; Employment; Contingency management **50**, 73

Methadone treatment outcomes; Scotland; Injecting; Crime; HIV risk behaviour **50**, 47

Morphine; Analgesia; LY297802; Muscarinic agonist; Subjective drug effects; Abuse liability; Humans **50**, 129

Morphine dependence; Cannabinoid receptor binding; Cannabinoid agonist-stimulated [35S]GTPγS binding; Autoradiography; Cannabinoids; Δ9-Tetrahydrocannabinol; Opiates **50**, 241

Muscarinic agonist; Analgesia; Morphine; LY297802; Subjective drug effects; Abuse liability; Humans **50**, 129

Naloxone; Buprenorphine; Opioid-dependence; Treatment **50**, 1

Neighborhood characteristics; Acquired immunodeficiency syndrome; Injection drug users; Human immunodeficiency virus; Geographic information systems; Attrition; Selection bias **50**, 167

Neuropsychological; Drug abusers; Polysubstance abuse; Cocaine **50**, 39

Nicotine abstinence; Methadone self-administration; Nicotine; Humans **50**, 157

Nicotine; Methadone self-administration; Nicotine abstinence; Humans **50**, 157

Opiates; Cannabinoid receptor binding; Cannabinoid agonist-stimulated [35S]GTPγS binding; Autoradiography; Cannabinoids; Δ9-Tetrahydrocannabinol; Morphine dependence **50**, 241

Opiates; Heroin; HIV-1; Evoked potentials; EEG; Drug abuse **50**, 147

Opiate withdrawal; Lofexidine; Clonidine; Ambulatory detoxification **50**, 251

Opiate withdrawal; Polydrug abusers; Methadone; Lofexidine **50**, 227

Opioid-dependence; Buprenorphine; Naloxone; Treatment **50**, 1

Opioid; Fluoxetine; Cocaine; Methadone; Depression **50**, 221

Opioids; Methadone maintenance; Substance abuse; Drug dosage; Gender **50**, 233

Opioid withdrawal syndrome; Rats; Control of withdrawal effects; Tizanidine **50**, 81

Perfusion defects; Cerebral; Cocaine; Alcohol; Abstinence **50**, 187

Polydrug abusers; Opiate withdrawal; Methadone; Lofexidine **50**, 227

Polysubstance abuse; Drug abusers; Neuropsychological; Cocaine **50**, 39

Predictors; Marijuana cessation; Reasons for using; Frequency of marijuana use; Social roles **50**, 109

Prenatal exposure; Cocaine; Intelligence; Child development **50**, 203

Prison; HIV transmission; Mathematical model; Injecting; Syringe sharing **50**, 197

Psychopathology; Cocaine; Dependence; Treatment; Comorbidity **50**, 9

Rats; Opioid withdrawal syndrome; Control of withdrawal effects; Tizanidine **50**, 81

Reasons for using; Marijuana cessation; Predictors; Frequency of marijuana use; Social roles **50**, 109

Reinforcement (psychology); Marijuana; Drug dependence; Conduct disorder **50**, 27

RTI-15; Cocaine; Drug discrimination; Locomotor activity **50**, 123

Scotland; Methadone treatment outcomes; Injecting; Crime; HIV risk behaviour **50**, 47

Screening; Computers; Acceptability; Clinical; Drug and alcohol **50**, 177

Selection bias; Acquired immunodeficiency syndrome; Injection drug users; Human immunodeficiency virus; Geographic information systems; Attrition; Neighborhood characteristics **50**, 167

Self-control; Impulsivity; Substance dependence; Substance abuse; Adult **50**, 137

Serotonin; β-Carbolines; Harmaline; Harmine; Drug discrimination; Hallucinogens; 5-HT_2 receptors **50**, 99

Social roles; Marijuana cessation; Predictors; Reasons for using; Frequency of marijuana use **50**, 109

Structural equation modeling; Alcohol; Dependence; Consequences; Bi-axial **50**, 211

Subjective drug effects; Analgesia; Morphine; LY297802; Muscarinic agonist; Abuse liability; Humans **50**, 129

Substance abuse; Impulsivity; Self-control; Substance dependence; Adult **50**, 137

Substance abuse; Methadone maintenance; Opioids; Drug dosage; Gender **50**, 233

Substance dependence; Impulsivity; Self-control; Substance abuse; Adult **50**, 137

Substance use; Adolescence; Development; Latent growth modeling **50**, 57

Syringe sharing; HIV transmission; Prison; Mathematical model; Injecting **50**, 197

***Δ*9-Tetrahydrocannabinol**; Cannabinoid receptor binding; Cannabinoid agonist-stimulated [35S]GTPγS binding; Autoradiography; Cannabinoids; Opiates; Morphine dependence **50**, 241

Tizanidine; Opioid withdrawal syndrome; Rats; Control of withdrawal effects **50**, 81

Treatment; Buprenorphine; Naloxone; Opioid-dependence **50**, 1

Treatment; Cocaine; Dependence; Psychopathology; Comorbidity **50**, 9